Skip to content

Earnings yield at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
5.9%+1.6pp
Supernus Pharmaceuticals logo
Supernus PharmaceuticalsSUPN
-1%-4.4pp
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
-6.9%-1.6pp
Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX
-3.6%-1.7pp
Biohaven logo
BiohavenBHVN
-50.9%+34.7pp
Septerna, Inc. logo
Septerna, Inc.SEPN
-3.3%-1.6pp

Other financials

Income statement

See full
Revenue$20.0M
Operating income-$24.2M+10.7%
Net income-$19.9M+17.5%
EPS (diluted)-$0.42+38.2%

Balance sheet

See full
Cash & equivalents$78.1M+35.5%
Total debt$10.8M+37.8%
Total equity$471.5M+65.0%
Total assets$497.6M+64.7%

Cash flow

See full
Operating cash flow-$13.1M+35.5%
CapEx$86.0K-70.4%
Free cash flow-$13.1M+36.0%

Valuation

See full
Market cap$1.91B+309%

Returns & leverage

See full
Return on equity-28.3%
Debt / equity0.0×
Current ratio27.1×-3.9×

Where this comes from

Calculated from Rapport Therapeutics, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Rapport Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rapport Therapeutics, Inc.'s earnings yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rapport Therapeutics, Inc.'s earnings yield?
Rapport Therapeutics, Inc. (RAPP) reported earnings yield of -7.2% in Q1 2026.
How has Rapport Therapeutics, Inc.'s earnings yield changed year-over-year?
Rapport Therapeutics, Inc.'s earnings yield increased by 67.1% year-over-year, from -21.8% to -7.2%.
What does earnings yield mean?
Trailing-twelve-month net income divided by market capitalization at the quarter end — the inverse of the P/E ratio, expressed as a percentage.